---
title: "MYD88"
date: 2023-05-14 00:00:00
layout: post
categories: Gene
summary: "## Gene: MYD88"
tags: ['MYD88', 'InnateImmuneResponse', 'Lymphoma', 'AutoimmuneDisorders', 'TherapeuticAgents', 'DrugResponse', 'Prognosis', 'Mutation']
---

## Gene: MYD88

### Genetic Position: 

Chromosome 3 (NC_000003.12): 38,382,814 - 38,395,562

### Pathology: 

MYD88 gene mutations are associated with various diseases such as lymphoma, leukemia, and certain autoimmune disorders.

### Function: 

MYD88 plays a crucial role in the innate immune response by activating the downstream signaling pathways that trigger the production of proinflammatory cytokines.

### Aliases and External IDs: 

- Aliases: MYD88, MYD88D
- HGNC ID: 7556
- NCBI Entrez Gene ID: 4615
- Ensembl ID: ENSG00000172936
- OMIM ID: 602170
- UniProtKB/Swiss-Prot ID: Q99836

### AA mutations: 

- Missense mutations:
  * p.L265P (rs34536443)
  * p.P217T (rs61753344)
- Frameshift mutations:
  * p.L252fs (rs757316172)

### Somatic SNVs/InDels:

- c.773G>A (rs143155428)
- c.818A>G (rs72571586)

### Related disease: 

- B-Cell Lymphoma
- Waldenstr√∂m Macroglobulinemia
- Gastric MALT Lymphoma
- Autoimmune Disorders (such as rheumatoid arthritis and systemic lupus erythematosus)

### Treatment and prognosis: 

MYD88 inhibitors are being developed as potential therapeutic agents for MYD88-associated lymphomas. The prognosis depends on the specific disease and individual patient factors.

### Drug response: 

Emerging evidence suggests that MYD88 inhibitors such as IMO-8400 and MEDI9197 may have potential therapeutic effects for MYD88-associated lymphomas.

### References:

- Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011 Mar 10;470(7332):115-9. doi: 10.1038/nature09671.
- Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018 May;560(7718):387-391. doi: 10.1038/s41586-018-0394-z. Epub 2018 Aug 1. PMID: 30069044; PMCID: PMC6210416.

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**